Literature DB >> 12035944

Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man?

C Ursing1, S Härtter, C von Bahr, G Tybring, L Bertilsson, S Röjdmark.   

Abstract

Melatonin (MT) is metabolized in the liver by cytochrome P450 (CYP) 1A2 but its importance for the metabolic process has not been fully elucidated. Therefore, the objective of this investigation was to study whether patients with different CYP1A2 activity would have different nocturnal serum MT levels. For that purpose serum MT concentrations were determined every second hour during the night in 12 healthy subjects and their MT areas under the curve (MT-AUCs) were calculated. Caffeine (CA) clearance was determined in advance. It is generally accepted that CA clearance reflects CYP1A2 activity. This made it possible to evaluate whether a relationship prevails between endogenous MT-AUCs and CYP1A2 activity. If CYP1A2 is of importance for the metabolism of MT one would expect to find an inverse correlation between the MT-AUCs and the CA clearance. However, such correlation did not exist in the current study (Rs=-0.021, NS). Since endogenous MT-AUC is dependent not only on MT elimination by CYP1A2 but also on MT secretion, it is possible that an increased MT secretion counter-balances an increased hepatic MT metabolism. If so, this could explain why the MT-AUCs and the CA clearance values were not inversely correlated in this study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12035944     DOI: 10.1007/BF03344038

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

1.  Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.

Authors:  S Härtter; X Wang; H Weigmann; T Friedberg; M Arand; F Oesch; C Hiemke
Journal:  J Clin Psychopharmacol       Date:  2001-04       Impact factor: 3.153

2.  Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1.

Authors:  L Gu; F J Gonzalez; W Kalow; B K Tang
Journal:  Pharmacogenetics       Date:  1992-04

3.  Melatonin and cortisol increase after fluvoxamine.

Authors:  K Demisch; L Demisch; H J Bochnik; T Nickelsen; P H Althoff; K Schöffling; R Rieth
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Human melatonin suppression by light is intensity dependent.

Authors:  I M McIntyre; T R Norman; G D Burrows; S M Armstrong
Journal:  J Pineal Res       Date:  1989       Impact factor: 13.007

5.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.

Authors:  U Jeppesen; L F Gram; K Vistisen; S Loft; H E Poulsen; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.

Authors:  S Härtter; C Ursing; S Morita; G Tybring; C von Bahr; M Christensen; S Röjdmark; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2001-07       Impact factor: 6.875

7.  Increased bioavailability of oral melatonin after fluvoxamine coadministration.

Authors:  S Härtter; M Grözinger; H Weigmann; J Röschke; C Hiemke
Journal:  Clin Pharmacol Ther       Date:  2000-01       Impact factor: 6.875

Review 8.  The use of caffeine as a metabolic probe for human drug metabolizing enzymes.

Authors:  J O Miners; D J Birkett
Journal:  Gen Pharmacol       Date:  1996-03

9.  Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Authors:  D J Skene; C J Bojkowski; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

10.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors:  K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

View more
  4 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.

Authors:  Chao Wang; Xiaokui Huo; Xiangge Tian; Min Xu; Peipei Dong; Zhilin Luan; Xiaobo Wang; Baojing Zhang; Bo Zhang; Shanshan Huang; Sa Deng; Xiaochi Ma
Journal:  Br J Pharmacol       Date:  2016-10-10       Impact factor: 8.739

Review 3.  Melatonin Therapy in Patients with Alzheimer's Disease.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Luis I Brusco
Journal:  Antioxidants (Basel)       Date:  2014-04-10

4.  Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.

Authors:  Gaëlle Magliocco; Jules Desmeules; Caroline Flora Samer; Aurélien Thomas; Youssef Daali
Journal:  Clin Transl Sci       Date:  2022-03-26       Impact factor: 4.438

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.